Hasbro reported second-quarter 2025 earnings with net revenue of $980.8 million, surpassing estimates of approximately $875 million, and adjusted EBITDA of $302 million, well above the $228 million forecast. Despite a net loss of $855.8 million mainly due to a $1 billion goodwill impairment and tariff charges, the company raised its full-year revenue outlook to mid-single-digit growth and adjusted EBITDA guidance to between $1.17 billion and $1.20 billion. Strong demand for its "Magic: The Gathering" and Wizards of the Coast digital gaming products drove the positive results, supported by cost-cutting measures and diversified manufacturing that helped mitigate tariff impacts. Amphenol posted robust second-quarter results with net sales of $5.65 billion, exceeding estimates of $5.04 billion, and adjusted EPS of $0.81 versus an expected $0.67. The company achieved record sales and profitability, driven by strong organic growth across all markets and successful acquisitions, particularly benefiting from the AI and data center boom. It provided a positive outlook for the third quarter with expected sales between $5.48 billion and $5.58 billion. Mattel reported adjusted EPS of $0.19, beating estimates of $0.15, but net sales fell 6% to $1.02 billion, slightly below the $1.05 billion forecast. The company reinstated its full-year sales outlook with a modest increase of 1% to 3% in constant currency and adjusted EPS guidance between $1.54 and $1.66, reflecting ongoing uncertainty from tariffs and weaker retailer demand. Growth in Hot Wheels offset declines in Barbie and Fisher-Price categories, while gross margin expanded to 50.9% due to cost savings. Separately, Oppenheimer upgraded Carvana to Outperform from Perform, setting a price target of $450, citing its unique position as a digitally driven disruptor in the used car market with strong cash generation and growth potential.
$EW -Mizuho raises Edwards Lifesciences target to $95 from $87 Outperform -Barclays raises target to $95 from $90 Overweight -Deutsche Bank raises target to $94 from $85 Buy -Stifel raises target to $95 from $90 Buy -Piper Sandler raises target to $90 from $83 Overweight
$ELV -Baird lowers Elevance Health target to $297 from $492 Neutral - $EME -UBS raises EMCOR target to $715 from $570 Buy - $ENVX -Benchmark raises Enovix target to $25 from $15 Buy - $EQT -Piper Sandler raises EQT target to $49 from $48 Neutral - $ESQ -Keefe Bruyette & Woods
$EL -JOMorgan upgrades Estee Lauder to Overweight from Neutral Raises target to $101 from $62 - $ELDN -Craig Hallum initiates Eledon Pharmaceuticals coverage at Buy $12 target - $ELF -JPMorgan raises e.l.f. Beauty target to $132 from $123 Overweight -